Colorectal cancer (CRC) is one of the most prevalent and deadly cancers in the world. Despite an expanding knowledge of its molecular pathogenesis during the past two decades, robust biomarkers to enable screening, surveillance, and therapy monitoring of CRC are still lacking.
In this study, we present a targeted liquid chromatography-tandem mass spectrometry-based metabolic profiling approach for identifying biomarker candidates that could enable highly sensitive and specific CRC detection using human serum samples. In this targeted approach, 158 metabolites from 25 metabolic pathways of potential significance were monitored in 234 serum samples from three groups of patients (66 CRC patients, 76 polyp patients, and 92 healthy controls).
To the best of our knowledge, this is the first report in which an LC–MS/MS targeted serum metabolic profiling approach has been applied for the comparison of CRC patients to both healthy controls and polyp patients, and our results demonstrate a panel of 13 serum metabolites for the differentiation of CRC patients and healthy controls and 14 for the differentiation of CRC and polyp patients. With the inclusion of four clinical factors (age, gender, smoking, and alcohol status), this metabolic profile can potentially serve as a novel disease biomarker panel for CRC diagnosis.
Citation & Full Text
Zhu, J., Djukovic, D., Deng, L., Gu, H., Himmati, F., Chiorean, E.G., Raftery, D.: Colorectal Cancer Detection using Targeted Serum Metabolic Profiling.J. Proteome Res. 13:4120-4130, 2014.